Danaher Appoints Daniel Comas and Robert Hershberg to Board of Directors

Danaher Corporation announced on October 12, 2026, the appointment of Daniel L. Comas and Robert Hershberg, M.D., Ph.D., to its Board of Directors, effective October 9, 2026. Dr. Hershberg was also appointed to the Company's Science and Technology Committee. Alan G. Spoon will not stand for re-election at Danaher's 2027 Annual Meeting of Shareholders and will retire from the Board at that time.

The company expanded its Board size from 11 to 13 directors to accommodate these appointments. Danaher's Nominating & Governance Committee is continuing to evaluate Board composition as part of its regular governance and refreshment processes. "Danaher has long benefited from a Board that brings together diverse experiences and perspectives relevant to our strategy and businesses," said Steven M. Rales, Chairman of the Danaher Board of Directors.

Comas, who joined Danaher in 1991 and previously served as Executive Vice President and Chief Financial Officer, brings extensive knowledge of the company, the Danaher Business System, and capital allocation strategies. Hershberg, with a background in senior executive roles in biotechnology and biopharmaceutical development, adds scientific, clinical, and biopharmaceutical expertise to the Board.

Steven M. Rales also expressed the Board's gratitude to Alan Spoon for his contributions to the company's growth and success during his tenure. Danaher co-founders Steven and Mitchell Rales have also waived certain restricted stock unit awards.